Over the last two decades, the global healthcare industry has evolved, leading to a growing demand from regulatory agencies, HTA agencies, and payers to actively demonstrate the real-world value and safety of medicines, devices, and other health products. The LA-SER Group has emerged and developed along with this changing healthcare landscape, growing to meet the needs of clients in the pharmaceutical, medical device, and biotechnology industries.
Building on the experience of the initial, near-academic company The Centre for Risk Research Inc., founded in 1992 in Montreal (Canada) by Lucien Abenhaim, the LA-SER team was created in 2004 in Paris and established its headquarters in London (UK) in 2009. Since that time, LA-SER has engaged in a series of mergers and acquisitions in order to expand the organization’s capabilities in health outcomes research, analytics, and strategy consulting. Currently, the LA-SER Group’s team is composed of over 200 highly-trained scientific staff with experience in a host of key disciplines including epidemiology, pharmacoepidemiology, clinical pharmacology, public health, biostatistics, health economics, quantitative social research, and others. Our research is presented at industry conferences and academic symposia, published in peer-reviewed journals, and cited by leading health technology assessment bodies.
With eight offices spanning three continents, the LA-SER Group is well-positioned to provide strategic consulting and scientific research services to the dedicated and highly motivated professionals in the global healthcare industry.
The LA-SER Group consists of three integrated business units: